Karolinska Development Details SEK 202M Rights Issue and Rebrands as KDventures
Solna, Friday, 9 January 2026.
Rebranding as KDventures, the firm targets SEK 202.6 million in fresh capital. Investors face a 5:2 subscription ratio to fund Nordic life science expansion starting January 13.
Strategic Rebranding and Capital Injection
Karolinska Development AB (Nasdaq Stockholm: KDEV) is executing a significant strategic pivot, marking today, January 9, 2026, with the publication of an information document for a fully guaranteed rights issue [1]. This follows the Extraordinary General Meeting (EGM) held yesterday, January 8, where shareholders approved both the capital raise and a corporate name change to KDventures AB [2][3]. The company aims to secure gross proceeds of approximately SEK 202.6 million before transaction costs to fuel its investment activities in the Nordic life sciences sector [1]. This rebranding to KDventures AB signals a renewed commitment to identifying and backing breakthrough medical innovations across the region [3].
Structure of the Rights Issue
The specific terms of the offer, initially resolved by the Board on December 1, 2025, and ratified at the recent EGM, provide existing shareholders with preferential subscription rights [2]. For every existing share held, shareholders receive five subscription rights; subsequently, two subscription rights are required to subscribe for one new series B share [2]. The subscription price is set at SEK 0.30 per share [3]. With a maximum issuance of 675,193,985 new shares, the total capital raised could amount to 202.558 million SEK [2]. The share began trading on Nasdaq Stockholm excluding these subscription rights yesterday, January 8 [4].
Critical Timeline for Investors
Investors must navigate a tight schedule following today’s regulatory filing. The subscription period for the new shares is slated to run from January 13 through January 27, 2026 [1]. Concurrent with this window, trading in the subscription rights themselves will occur between January 13 and January 22, 2026 [1]. Furthermore, trading in paid subscribed shares (BTA) is scheduled to commence on January 13 and continue until approximately February 12, 2026 [1]. The company anticipates announcing the final outcome of the rights issue on or around January 29, 2026, with the new shares expected to begin trading on February 16, 2026 [1].
Portfolio Context and Advisory
The capital raised is intended to support a portfolio that currently includes eleven companies, as they progress toward commercializing their assets [2]. Recent operational highlights within this portfolio include positive Phase IIa results from AnaCardio [5]. To manage the intricacies of this transaction, the company has engaged Redeye AB as the financial advisor and Cirio Advokatbyrå AB as the legal advisor, while Nordic Issuing AB serves as the issuing agent [1]. The transition to the KDventures identity reflects the firm’s evolving role in building and financing companies that address life-threatening or debilitating diseases [3].